Pulmonary Hypertension Linked to Mortality After Atrial Septal Defect Repair
Persistent pulmonary hypertension is strong predictor of mortality in older patients who underwent ASD closure.
Pulmonary Arterial Hypertension
FDA to Review Drug-Device Combo for Pulmonary Arterial Hypertension Treatment
The FDA has accepted for review the New Drug Application for Trevyent, a drug-device combination product for the treatment of pulmonary arterial hypertension.
Sotatercept Receives Orphan Drug Status for Pulmonary Arterial Hypertension
The FDA has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Ralinepag Reduces Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension
Treatment with the next-generation potent prostacyclin receptor agonist ralinepag reduced pulmonary vascular resistance compared with placebo in patients with symptomatic pulmonary arterial hypertension.
Pulmonary Arterial Hypertension in Women: New Approaches to Care
Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women.
Implantable Hemodynamic Sensor May Guide Therapy in PAH With Right-Sided HF
An implantable hemodynamic monitor safely monitored hemodynamic changes in patients with severe pulmonary arterial hypertension.
Do Patients With Idiopathic PAH Have Worse Lung Transplantation Outcomes?
Patients with idiopathic pulmonary artery hypertension undergoing a lung transplant in which extracorporeal life support is needed experienced poorer outcomes compared with patients with other diagnoses.
Childhood Pulmonary Hypertension Subtypes, Survival Vary by Race/Ethnicity
There is significant variation by race and ethnicity in the prevalence of childhood pulmonary hypertension subtypes and survival outcomes.
Domiciliary Oxygen Increases Exercise Capacity in Pulmonary Hypertension
Patients with pulmonary arterial or distal chronic thromboembolic pulmonary hypertension were able to increase 6-minute walk distance and improve physical status on domiciliary oxygen therapy.
BET Inhibitor Reverses Vascular Remodeling in Pulmonary Arterial Hypertension
At a clinically relevant dose, RVX208 improved hemodynamics and reversed pulmonary vascular remodeling in certain pulmonary arterial hypertension models in rats.
Next post in Pulmonary Hypertension
